Off-the-shelf Lead mAbs, Ready to Licensing Out

Antibody drugs are one of the most revolutionary breakthroughs in biopharmaceuticals. With their high specificity, low toxicity, and broad therapeutic potential, they have become the fastest-growing segment of the global pharmaceutical market. However, antibody drug development is a costly and time-consuming undertaking, with the preclinical development phase alone taking at least three to five years and requiring millions, if not tens of millions, of dollars in investment.

To help pharmaceutical companies accelerate the preclinical development of antibody drugs, DIMA BIOTECH has launched the “All Druggable Targets” lead antibody molecule development program, leveraging its proprietary, innovative single B cell development platform. DIMA BIOTECH will generate lead antibody molecules and corresponding B cell seed libraries targeting all druggable targets. Clients can directly import lead antibody molecules from DIMA BIOTECH or rapidly screen for additional lead antibodies from the B cell seed library. Compared to traditional hybridoma technology, DIMA BIOTECH can save clients up to nearly a year in development time.